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ABSTRACT
Aim: to investigate the events involved in the progression of myxoid liposarcoma 
(MLS). 
Gene expression profiling and immunohistochemical/biochemical analyses were 
applied to specimens representative of the opposite ends of the MLS spectrum: pure 
myxoid (ML) and pure round cell (RC) liposarcomas.
The analyses revealed the involvement of both coding and non coding RNAs 
(SNORDs located in DLK1-DIO3 region) and support a model of stepwise progression 
mainly driven by epigenetic changes involving tumour vascular supply and tumoral 
cellular component. In this model, a switch in the vascular landscape from a normal 
to a pro-angiogenic signature and the silencing of DLK1-DIO3 region mark the 
progression from ML to RC in concert with the acquisition by the latter of the over-
expression of YY1/C-MYC/HDAC2, together with over-expression of genes involved 
in cell proliferation and stemness: MKNK2, MSX1 and TRIM71.
Taken together, these findings strongly suggest that to progress from ML to RC 
liposarcoma the cells have to overcome the epigenetic silencing restriction point in 
order to reset their new stem-like differentiation signature. Our findings provide a 
first attempt at identifying the missing links between ML and RC liposarcomas, that 
may also have broader applications in other clinico-pathological settings characterised 
by a spectrum of progression.
INTRODUCTION 
Myxoid liposarcomas (MLS) encompass myxoid 
(ML) and round cell (RC) variants initially believed 
to be distinct diseases [1] and currently regarded as the 
well- and the poorly-differentiated extremes of a single 
spectrum. Molecularly MLS is characterised by the 
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recurrent FUS-DDIT3 and rarely (10%) EWSR1-DDIT3 
balanced translocations. Within the spectrum of MLS, the 
fusion proteins that make the cells “immature” by blocking 
lipogenic differentiation play a role in tumour initiation, 
but little is known about the molecular determinants 
associated with their progression to RCs.
Activation of the AKT pathway sustained by 
PIK3CA [2] and PTEN [3,4] mutations, and signalling 
by growth factor receptors such as RET and IGF1R, have 
been recently correlated with the increased aggressiveness 
of RC [3-5]. In the clinical setting, however, the most 
significant predictor of a poor outcome in patients with 
MLS remains the amount of round cell (RC) component 
(>5%) as this increases the risk of metastases [6]. It worth 
noting that the five-year survival rate among patients with 
MLS ranges from 20-70%, and is shortest in those with 
RC [7]. 
To develop a predictor of outcome in liposarcoma 
patients, Gobble et al. analyzed microarray-based gene 
expression profiling of 140 samples [8]. This case material 
included 17 ML and 12 RC defined as MLS with RC 
component >5%.
The aim of this study is to elucidate the molecular 
events involved in RC progression by means of 
microarray-based gene expression profiling and gene-
by-gene hypothesis-driven analysis. Two small series 
of MLS specimens (the first used for the training and 
the second for validation) were selected in such a way 
as to be representative of the two extremes of the MLS 
spectrum: pure myxoid (about 0% of RC component) and 
RC specimens (≥80% of RCs) [1]. 
RESULTS
Identification of gene expression profiles 
differentially expressed in myxoid and round cell 
liposarcomas
Figure 1 shows the workflow of the study. In order 
to identify the gene expression pattern modulated in ML 
and RC liposarcomas, a training set of 12 FFPE samples 
(6 ML and 6 RC; case material INT-A, see Supplementary 
Table S1 for the clinical/pathological/molecular 
characteristics of the patients) was initially selected and 
profiled using the Illumina whole-genome DASL assay. 
In this dataset, 16,859 transcripts were detected, and 307 
probes, corresponding to 298 unique genes, were identified 
as differentially expressed by means of class comparison 
analysis using a false discovery rate (FDR) of <10%: 
115 probes up-regulated in RC and 192 up-regulated in 
ML (Figure 2A). The probability of finding 307 probes 
significant by chance if there were no real differences 
between the classes was 0.00649, as determined by the 
global test. Principal component analysis (PCA) indicated 
that the samples were distributed in two main clusters 
matching the ML and RC samples (Figure 2B). 
For validation purposes, we assessed the extent 
to which the molecular patterns differentially expressed 
in the training set were similar to those in a new cohort 
of 12 frozen samples (6 ML and 6 RC; case material 
INT-B, see Supplementary Table S2), and a public 
dataset (GSE30929) [8] containing 17 ML and 12 RC 
liposarcomas. Both data sets were first analysed separately 
Figure 1: Study outline 
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in order to define the genes differentially expressed in 
ML and RC liposarcomas. By imposing a FDR of <10%, 
we identified 64 genes in INT-B and 58 in GSE30929 
(Supplementary Figure S1). Using a bioinformatic 
method that assesses the correspondence of molecular 
patterns in different datasets (subclass mapping), we found 
significant regulation of the same genes (Figures 2C and 
2D), thus providing evidence of the reliability of the genes 
differentially expressed in the training set. 
Selection of genes for protein analysis
A list of the 174 modulated genes in the ML and RC 
variants was generated by applying a filter based on a |log2 
(fold change)|>2 and a permutation p-value <0.001 to the 
INT-A data set (Supplementary Table S5). On the basis of 
published data and given the biological characteristics of 
MLS, we focussed on the most differentially expressed 
genes in three main categories: i) those involved in 
angiogenesis; ii) those located in the DLK1-DIO3 region 
Figure 2: (A and B) Genes differentially expressed in the INT-A dataset. (A) Heatmap of the genes differentially expressed after 
imposing an FDR of <0.1. (B) The differentially expressed genes visualised by PCA divided the samples into two well-defined groups 
corresponding to ML (blue) and RC (red). Sub-class mapping (SubMap) analysis comparing the genome-wide molecular pattern identified 
in INT-A with the patterns identified in the INT-B (C) and GSE30929 data sets (D). Red indicates high confidence in correspondence; blue 
indicates a lack of correspondence. P values are given in the boxes.
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on chromosome 14q32; and iii) those involved in cell 
proliferation and staminal status. These were validated in 
the INT-A and INT-B series by means of qRT-PCR and the 
results are shown in Table 1. The differential expression 
was tested at protein level by IHC and/or WB for all 
markers, but TRIM71 and non coding RNAs (SNORDs) 
of DLK1-DIO3 region.
Angiogenesis
Angiogenic factors up-regulated in ML: EGFL7 and 
EGFL6
EGFL7 is a protein that is almost exclusively 
expressed by endothelial cells and which, by means 
of NOTCH signalling, represses VEGFR pathway and 
stabilises developing vessels by maintaining the junctions 
between endothelial cells [11]. The vascular regulatory 
function of EGFL7 is reinforced by hsa-miR-126, which 
plays a role in correct vessel formation by modulating 
the response to growth factors (the VEGFA/VEGFR2 
axis) and reducing the expression of endothelial cell 
adhesion molecules (V-CAM) [12-15]. In line with this 
involvement, hsa-miR-126 was down-modulated in RC as 
assessed by qRT-PCR (Table 1).
EGFL6 is a secreted protein whose receptor is not 
yet been defined. It is produced by mesenchymal cells 
[16], and promotes correct endothelial cell migration and 
tube formation by activating the ERK pathway [16]. It 
has been reported that its over-expression in tissue and 
serum correlates with benignity within the spectrum of 
meningiomas [17]. Like EGFL7, EGFL6 harbours a 
miRNA (hsa-miR-6086) that was down-modulated in RC 
as assessed by qRT-PCR (Table 1), but whose role has not 
yet been fully clarified. 
Table 1: Evaluation of differentially expressed genes /miRNAs involved in the proposed model of ML to RC progression, 
at RNA and protein level.
Gene/miRNA
microarrays 
Fold change (RC/ML m)
RTq-PCR 
Training set (RC/ML)
RTq-PCR 
Validation set (RC/ML)
Protein 
evaluation
Training set Validation set
Geometric 
mean of 
ratios
Parametric 
p-value
Geometric 
mean of 
ratios
Parametric 
p-value
Angiogenesis
EGFL6 0.068 0.17 0.042 0.0010987 0.0086 0.0010582 IHC
EGFL7 0.21 0.89 0.07 0.0005039 0.44 0.0463813 IHC
hsa-miR-6086# 
(EGFL6) ND ND 0.22 0.0146451 ND ND NA
hsa-miR-126# 
(EGFL7) ND ND 0.13 0.012225 ND ND NA
GREM2 5.37 2.94 8.88 0.0085956 6.26 0.0023144 IHC/WB/IF
HOXB7 5.86 1.58 4.16 0.0088443 1.6 0.0886894 IHC
DLK1-DIO3 region
SNORD113-7 0.19 ND 0.067 0.0019721 0.081 0.0258624 NA
SNORD113-5 0.17 ND 0.1 0.0021936 0.2868659 0.33 NA
SNORD112 0.11 ND 0.045 0.0148743 0.2573069 0.28 NA
SNORD114-31 0.2 ND 0.19 0.0904756 0.264131 0.27 NA
hsa-miR-134 ND ND 0.38 0.0352731 ND ND NA
hsa-miR-382 ND ND 0.14 0.0020194 ND ND NA
hsa-miR-544 ND ND 0.37 0.0329153 ND ND NA
Cell proliferation and stemness related genes
YY1 1.94 NA 21.26 0.0065292 7.24 0.0565113 IHC/WB/IP
MSX1 8.66 2.97 9.9 0.0344053 4.21 0.0149181 IHC
MKNK2 4.68 1.82 3.88 0.0055919 1.96 0.0075854 IHC/WB
TRIM71 4.4 NA 2.65 0.0044 1.85 0.0464 ND
C-MYC 1.1 1.34 0.744 0.75 0.52 0.109472 IHC/WB
HDAC2 1.35 0.9 1.53 0.84 0.92 0.32 IHC/WB/Functional assay
Abbreviations: ND: not determined; NA: not applicable; IHC: immunohistochemistry; WB: western blotting; IF: 
immunofluorescence; IP: immunoprecipitation
# intragenic miRNA, in brackets the hosting gene  
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We were unable to obtain acceptable 
immunostaining for both of these factors, as often occurs 
when dealing with antibodies against ligands.
Angiogenic factors up-regulated in RC: Gremlin and 
HOXB7
Gremlin, which is known to act as an antagonist 
of BMP, may also function as a non-canonical VEGFR2 
agonist [18] as it can induce the formation of the VEGFR2/
αVß3 integrin complex that mediates paracrine/autocrine 
function in tumour vascularisation [19]. IHC showed 
that gremlin was expressed in the extra-cellular matrix, 
tumoral cells and vessels (Supplementary Figure S2 A,B) 
as previously described [20], and WB confirmed that it 
was more expressed in RC than in ML (Supplementary 
Figure S2 C). Confocal microscopy revealed the co-
localisation of VEGFR2 and gremlin, a finding that 
suggests the gremlin-mediated enhancement of VEGFR2 
activation (Supplementary Figure S2 panels D, E and F). 
As regards HOXB7, we hypothesise that, in 
our context, this gene plays an oncogenic role by 
acting as a hub enhancing the activation of multiple 
factors (Supplementary Table S6). It has recently been 
demonstrated that the forced expression of HOXB7 in 
multiple myeloma induces the up-regulation of VEGFA, 
FGF2, MMP2 and PDGFA, and the down-regulation 
of thrombospondin 2 [26], a profile largely shared by 
RC [38]. IHC analysis confirmed the molecular data by 
showing more tumoral cells with nuclear decoration in 
RC than in ML (Supplementary Figure S2 panels H and 
G), which suggests that HOXB7 plays a paracrine role 
although it may also be involved in regulating stemness.
Taken together, this evidence indicates that the 
progression from ML to RC is marked by changes that 
go from the “physiological-like” expression of proteins 
involved in regulating a proper vessel wall formation and 
function to the expression of proteins which, together 
with endothelial proteins and other factors, favour the 
development of an activated vascular phenotype [39].
The DLK1-DIO3 region 
The DLK1-DIO3 genomic region located on human 
chromosome 14 (14q32) contains the paternally expressed 
imprinted genes DLK1, DIO3 and RTL1, the maternally 
expressed imprinted long non-coding (lnc) RNA MEG3 
and MEG8 genes and anti-sense RTL1, and one of the 
largest miRNA clusters in the genome: 54 miRNAs and 
41 SNORDs. 
This region is aberrantly expressed in most cancers 
and, although its function is not entirely understood, 
believed to possess tumour suppressor properties [40].
qRT-PCR confirmed microarray data showing that 
four SNORDs (SNORD 113-7, 113-5, 112 and 114-31) 
were more expressed in ML than in RC. Three miRNAs 
described to be located in this region (hsa-miR-134, hsa-
miR-382 and hsa-miR-544) [40] were also assessed by 
qRT-PCR and found out again overexpressed in ML (Table 
1).
However, when the region was analysed by means 
of FISH, no changes in copy number were found in either 
ML or RC (data not shown). 
This evidence cumulatively supports the idea that 
the active state of the DLK1-DIO3 region in ML reduces 
cell proliferation and, as suggested by published data, that 
this epigenetic silencing is probably mediated by lnc RNA 
associated with chromatin-modifying complexes [41]. 
Cell proliferation and stemness-related genes 
Gene expression analysis and qRT-PCR indicated 
that genes involved in pluripotency and fast cell cycle 
(YY1, MKNK2, MSX1 and TRIM71) were up-regulated in 
RC variant (Table 1). This segregation, coupled with the 
down-regulation of 14q32 region, strongly suggests that 
removing this restriction point is essential for resetting the 
epigenetic and transcriptional status of RC cells. 
YY1 and YY1 interacting proteins
YY1 over-expression in RC was confirmed by IHC 
(Figure 3A, B) and Western blotting (Figure 3C). YY1 is 
a transcription factor that modulates the transcription of 
other genes (Supplementary Figure S3, Supplementary 
Table S6) and acts by interacting with other proteins 
(Figure 3 D). In particular, it may interact with c-MYC 
(Figure 3D, left) and thus contribute to activating their 
shared target genes, and with HDAC2 (a PRC2 interacting 
protein) (Figure 3D, right) in order to suppress gene 
expression. In addition, c-MYC and HDAC2 have a 
mutual positive regulatory function. 
c-MYC 
Despite the absence of c-MYC modulation at RNA 
level (Table 1), and given that YYI and c-MYC co-
localise on the same promoters, that the over-expression 
of YY1 activates both endogenous and exogenous c-MYC 
promoters, and that the protein encoded by c-MYC can 
be post-translationally stabilised [42-44], we analysed 
c-MYC at protein level. Immunophenotyping revealed 
only rare, scattered c-MYC-immunolabelled nuclei in 
ML (Figure 4 A), whereas the overwhelming majority of 
nuclei were decorated in RC (Figure 4, B and B’), thus 
suggesting the post-translational stabilisation of C-MYC 
[44]. This result was confirmed by Western blotting 
(Figure 4C). IHC showed that c-MYC positivity correlated 
with an OCT4 and SOX2 null immunophenotype (data not 
shown), a signature that is consistent with that reported for 
c-MYC module [36] (Supplementary Table S6). 
Taken together, these results suggest that 
cooperation between YY1 and c-MYC plays a pivotal role 
in triggering a specific RC network that favours a fast cell 
cycle (see Figure 3D left, and E). 
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Figure 3: YY1. YY1 immunostaining shows faintly immunolabelled nuclei in the ML samples (A) and strong nuclear decoration in the 
RC samples involving the overwhelming majority of enriched tumoral cells (B). The results of the WB experiments were consistent with 
immunohistochemical results (C) Explanatory diagram of YY1 interactions. (D) The proposed model envisages mechanistic interactions 
between proteins and the promoters of the fast cell cycle/pluripotency/differentiation genes involved in MLS tumour progression. YY1 can 
activate (left) or repress (right) the transcription of its target genes. Left: Gene switch-on driven by YY1. YY1 triggers gene expression (“ON” 
genes) by recruiting histone acetyltransferases p300/CBP, which promote the histone acetylation and protein arginine methyltransferase 
PRMT 1 that lead to methylation at Arg3 of histone H4. The result is a high level of transcription activity supported by the hyper-acetylated 
and tri-methylated promoters shared by YY1 and c-MYC that leads to c-MYC network activation [32] involving fast cell cycle/pluripotency 
genes. Moreover, as c-MYC and HDAC2 play a mutually positive regulatory role, HDAC2 may activate c-MYC, thus making it a possible 
pharmacological target. TRIM71 is a downstream target that correlates significantly with YY1 (see Figure S3, described below). Right: 
Gene switch-off driven by YY1. PRC2 suppresses gene expression (“OFF” genes) by promoting histone H3 lysine 27 trimethylation 
(H3K27me3), and HDAC2 contributes to gene silencing by deacetylating histone. YY1 and HDAC2 physically interact and respectively 
bind PRC2 via Ezh2 and EED [28]. The result is silencing mediated by the deacetylation and tri-methylation of the promoters of the target 
genes involved in differentiation and fast cell cycle inhibition. Epigenetic modifications imposed by YY1, HDAC2 and c-MYC. (E) After 
each division, the fate of poised cells (translocation-carrying cells) is defined by genes targeted by the annotated proteins (YY1, HDAC2, 
c-MYC), which ensure progression to RC by means of protein-specific interplays that favour the repression or activation of the targeted 
genes in cooperation with chromatin-modifying complexes (thick arrow) of chromatin regulators (polycomb, trithorax, HDAC, HAC) and 
chromatin markers (H3K27, H3K4, histone deacetylation, histone acetylation). Polycomb and HDAC respectively induce gene silencing 
by means of H3K27 tri-methylation and histone deacetylation, whereas trithorax and HAC respectively trigger gene activation by means 
of H3K4 tri-methylation and histone acetylation. Cumulatively, the progression to RC is dictated by the enrichment of activated fast cell 
cycle/stemness genes and the silencing of differentiation/slow cell cycle genes. 
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Figure 4: HDAC2. Only rare nuclei were immunoreactive for c-MYC in ML (A), whereas most of them were decorated in the RC 
samples (B, B’). The immunohistochemistry results were confirmed by WB (C). Co-IP experiment demonstrating a physical interaction 
between YYI and HDAC2 (D). Unlike the YYI- and c-MYC-immunolabelled samples, the HDAC2-immunolabelled samples showed 
nuclear decoration of the majority of tumoral cells in both ML (E) and RC (F). However, WB revealed HDAC2 over-expression in RC (G).
Oncotarget5972www.impactjournals.com/oncotarget
HDAC2
In order to substantiate our model further, we 
used HDAC2 as a surrogate of the PRC2 complex even 
though the gene expression analysis showed that it was 
not modulated (Table 1). HDAC2 is an additional partner 
of YY1 that has been reported to interact with YY1 
physically [45]. YY1 and HDAC2 interact with PRC2 
(respectively via Ezh2 and EED) to induce the silencing of 
differentiation-related genes (see Figure 3 D, right). After 
having confirmed the interaction between HDAC2 and 
YY1 by means of co-immunoprecipitation (Figure 4D), 
we used IHC (Figure 4A, B, B’ and E, F) and Western 
blotting (Figure 4, C and G) of both c-MYC and HDAC2 
(bearing in mind that c-MYC binds the promoter region 
of HDAC2 and regulates the expression of PRC2 via 
HDAC2 regulation) [46, 47]. The readouts showed that 
the expression of c-MYC and HDAC2 was increased 
in RC, which is in line with a functional repressing role 
of PRC2. In order to confirm this result, we treated the 
402-91 MLS cell line with vorinostat, an HDAC inhibitor 
[48, 49], and found a dose-dependent decrease in c-MYC 
protein (Figure 5A) and a reduction in cell growth (Figure 
5, B and C). 
Using HDAC2 as a surrogate to infer possible 
PRC2-induced silencing, we suggest that the YY1/c-
MYC/HDAC2 axis plays a role in favouring stemness by 
modifying (via HDAC2) the chromatin-associated PRC2 
that is known to silence differentiation-related genes, and 
provide evidence indicating a drug-induced slowing of 
proliferation. 
MKNK2
The gene expression analysis showed that MKNK2, 
a kinase that specifically phosphorylates eukaryote 
translation initiation factor 4E (eIF4E) at Ser 209, was 
over-expressed in RC (Table 1), and this was confirmed 
by IHC and Western blotting (Supplementary Figure S4 
A,A’, B,B’ and C). It has been demonstrated that eIF4E 
phosphorylation, which is dispensable for basal protein 
synthesis and cell viability, is necessary to increase the 
translation of the mRNAs involved in tumorigenesis, 
including c-MYC and MCL1 [50, 51]. Consistently, and 
as previously shown in the case of c-MYC, MCL1 was 
over-expressed in RC as assessed by WB (Supplementary 
Figure S4D). 
MSX1 
IHC showed that MSX1, over-expressed in RC at 
mRNA level (Table 1), is also increased at protein level 
(Supplementary Figure S5). MSX1 belongs to the HOX 
family, and its expression inhibits differentiation and thus 
leads to cells having properties similar to those of stem 
cells [52]. This inhibitory function is due to one of the 
Figure 5: Vorinostat treatment Reduced c-MYC expression in the 402-91 cell line after vorinostat (SAHA) treatment. (A) 
MTT assay of the 402-91 cell line treated with vorinostat (SAHA). (B) Growth curve of the 402-91 cell line after three (T1) and six days 
of vorinostat (SAHA) treatment (T2) (C).
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most frequent mechanisms used by HOX genes to repress 
target genes: lnc RNA binding PRC2 (Supplementary 
Table S6 and Figure 3D). This is supported by the findings 
of recent studies of embryonic stem cells showing that 
MSX1 acts in competition with YYI and, by removing 
the PRC2/H3K27m3 repressor complex from YY1 and 
recruiting it to itself, represses MSX1 target genes [53, 
54]. 
In our model, the co-overexpression of MSX1 and 
HDAC2 strongly suggests that they act together to force 
cells toward stemness. 
TRIM71
Interrogation of the association between the 
expression profile of YYI and its downstream targets 
(Figure S4) showed that TRIM71 is over-expressed in 
RC. TRIM71 is an RNA binding protein that is highly 
expressed in undifferentiated cells such as embryonic 
stem cells (ESCs) [55] and dynamically regulated during 
induced pluripotent stem cell (iPSC) reprogramming [55]), 
represses mRNAs regardless of the miRNA pathway [56] 
as well as modulates miRNA-mediated repression. It 
has been shown that TRIM71 functionally interacts with 
miRNA and the RISK complex which, as it contains Ago2 
protein, can post-transcriptionally repress the expression 
of the cell cycle regulator Cdkn1a, and thus promote G1-S 
transition and the rapid proliferation of ESCs [57].
It has recently been suggested that TRIM71 belongs 
to the MYC module [55], thus supporting the idea that 
it may play a role in RC progression as a regulator of 
stemness and of the cell cycle.
Taken together, all of the above findings suggest 
that the make-up of the RC variant closely mirrors that of 
normal undifferentiated stem cells, and that YY1/c-MYC/
HDAC2 axis, cell cycle-related MKNK2, stemness-related 
MSX1 and stemness/cell cycle-related TRIM71 are all 
involved in maintaining RC variant cells in a fast cycling 
and undifferentiated state.
DISCUSSION
To the best of our knowledge, this is the first 
attempt to track a progression pathway from ML to RC 
liposarcomas by comparing the transcription profile of the 
two extremes of the tumour spectrum: the “pure forms” of 
the two variants. In this progression, the silencing of the 
DLK1-DIO3 region marks the transition to an epigenetic/
transcriptional reprogramming, which is strongly aided 
by the involvement of genes promoting the fast cell cycle 
and pluripotency such as YY1 and YY1-associated genes, 
MKNK2, MSX1 and TRIM71. 
The shift from a “normal” phenotype to a pro-
angiogenic signature probably represents the initial step 
in the progression from ML to RC, while epigenetic-based 
chromatin changes and the activation of transcriptional 
networks ultimately allow the cells to acquire (or re-enter) 
a stem-like state.
One novel finding of our study is the evidence 
indicating the significant up-regulation of the genes 
located on 14q32 region in ML that imposes the silencing 
of proliferation and pluripotency genes. The absence of 
any changes in copy numbers and the up-regulation of 
SNORDs and miRNAs revealed by qRT-PCR indicate 
the need to investigate this region further by focusing on 
epigenetic changes and miRNAs. It has recently emerged 
that the epigenetic regulation of tumour suppressor 
miRNAs is a critical signalling pathway involved in 
tumorigenesis [41]. It has been shown that miRNAs work 
closely with epigenetic modifiers, and that lnc RNAs 
may be physically associated with chromatin-modifying 
complexes for the purposes of activation (via histone tri-
methylation or acetylation) or repression (via histone tri-
methylation or deacetylation). Given the relatedness of the 
gene signature of embryonic stem and cancer cells [32, 36] 
and the fact that epigenetic modifications may change with 
each division of a cell carrying a tumoral translocation 
[58], we can imagine that, in our model, the chance of the 
daughter cell progressing to RC or remaining ML at each 
cycle greatly depends on the interplay of proteins (YY1, 
c-MYC and HDAC2) in concert with the enrichment 
of the activated fast cell cycle/stemness genes and the 
silenced differentiation/slow cell cycle genes in the case 
of RC, or vice versa in the case of ML (see Figure 3E). 
Although it needs to be re-examined by mean of focused 
high throughput technologies, this view also provides an 
explanation for the infrequent occurrence of pure MLS 
variants (about 0% or ≥80% of the round cell component).
After overcoming the barrier of the 14q32 region, it 
seems that changes in the expression of YY1 transcription 
factor and YY1-related genes are jointly responsible for 
driving cancer cells into their new cell state.
The apparently contradictory role played by 
YY1 (due to its ability to carry out different functions 
depending on the recruited co-factor) is also in line with 
the proposed model. Although the post-transcriptional 
interplay between YY1 and c-MYC and between YY1 
and HDAC2 both favour tumour progression, the former 
activates the fast cell cycle/pluripotency genes, and the 
latter represses differentiation/fast cell cycle inhibitor 
genes. Consistently, the use of an HDAC inhibitor reduced 
cell growth. 
In addition to c-MYC and MLC1, MKNK2 (a key 
gene in protein synthesis correlated with the fast cell 
cycle) was also differentially over-expressed in RC.
A stemness trait was given to the RC signature 
by the segregation of this variant with MSX1 over-
expression, which was probably attributable to the 
competition between MSX1 and YY1 for PRC2.
Another marker of stemness that was significantly 
enriched and co-expressed with YY1 in RC was the 
TRIM71 gene, which was detected by interrogating the 
association between YY1 expression and its downstream 
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targets. In addition to stemness, it is thought that this 
gene also contributes to progression by promoting rapid 
proliferation via cdkn1 repression [57]. 
Taken together, the findings of this study strongly 
suggest that progression from ML to RC passes through 
a transition phase that in some way recapitulates the 
development/reprogramming of pluripotent stem cells in 
a human embryo [59] and that, in order to reset their new 
pathological stem-like differentiation signature, tumoral 
cells have to overcome the epigenetic silencing restriction 
site. This decommissioning seems to be a shared paradigm 
for tumours showing a spectrum of increasing malignancy 
[60-62] and epithelial-mesenchymal transition [63], and 
represents not only a prerequisite for progression towards 
higher grade/de-differentiated forms, but also a promising 
therapeutic target. The findings also suggest that the so-
called “primitive” or “immature” translocation carrying 
cells of MLS should rather be regarded as “partially 
immature” as they acquire a robust stem-like signature 
when they progress from ML to RC. 
Our gene discovery-based analysis only began 
to shed light on the multi-step process of ML-RC 
progression, which involves the complex interaction 
of genetic and epigenetic factors, but warrants further 
exploration.
METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board. In particular, the study was 
approved by the Independent Ethics Committee of the 
Fondazione IRCCS Istituto Nazionale dei Tumori di 
Milano (INT-MI). All of the patients whose biological 
samples were included in the study gave their signed 
consent to donate the tissues remaining after the diagnostic 
procedures had been completed at INT-MI. 
Patients and study design
A total of 24 patients undergoing the surgical 
resection of MLS were evaluated for this study. The 
sample areas chosen for the analysis contained more 
than 90% tumour cells, and no necrosis or normal tissue. 
The training series (INT-A) consisted of formalin-fixed 
paraffin-embedded (FFPE) surgical samples obtained 
from 12 patients treated at our institution between 1997 
and 2009. The morphological characteristics of the pure 
myxoid and RC groups satisfied our selection criteria in 
all but one case (#AU19), which had a lower percentage 
of RCs. The validation series (INT-B) consisted of 
cryopreserved surgical samples obtained from 12 patients 
managed at our institution between 1978 and 2011; six 
cases were pure ML and six were pure RC. 
Information about treatment and follow-up of 
the patients and molecular and molecular/cytogenetic 
characterisation of the samples are reported in 
Supplementary Methods. 
Tables S1 and S2 summarise the clinical data, 
treatment, follow-up, and molecular cytogenetic 
characteristics of the two series for INT-A and INT-B 
respectively. 
Gene expression analysis
The microarrays were run as described in 
Supplementary Methods.
Total RNA from 10 μm sections of the FFPE 
INT-A specimens was isolated using the Qiagen RNeasy 
FFPE (Qiagen, Valencia, CA, USA) following the 
manufacturer’s instructions, and was profiled on Illumina 
whole-genome DASL HumanHT-12 v4 BeadChips. Total 
RNA from the INT-B series was extracted from frozen 
samples using TriZol (Invitrogen), and was profiled on 
HumanHT-12_v4 BeadChips using the direct hybridisation 
assay.
All of the microarray data were MIAME compliant 
and the raw data were deposited into the NCBI’s GEO 
database (http://www.ncbi.nmlm.nih.gov/projects/geo/) 
with accession number [GSE55466].
Quantitative reverse-transcription PCR (qRT-
PCR) of gene and miRNA expression was performed as 
described in Supplementary Methods using the primers 
listed in Supplementary Table S3.
Bioinformatic analysis
Class comparison, hierarchical clustering, global test 
of clustering, and heat map analyses were performed as 
described in Supplementary Methods. Sub-class mapping 
was carried out using the algorithm developed by Hoshida 
[9.]. 
Immunohistochemistry (IHC)
Supplementary Table S4, part 1, shows the 
antibodies and experimental conditions used to detect 
gremlin, HOXB7, YY1, c-MYC, HDAC2, MKNK2 and 
MSX1. 
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Immunofluorescence (IF) and confocal 
microscopy 
The first part of the IF protocol was carried out 
as described for IHC in Supplementary Table S4. After 
being processed as previously described [3], the slides 
were incubated for 30 minutes at room temperature 
(RT) with rabbit anti-goat biotinylated antibody (E0466 
DAKO, Carpinteria, CA) (dilution 1:100), followed by 
Alexa Fluor 546 streptavidin for one hour at RT (dilution 
1:1000) (Invitrogen, Carlsbad, CA). Thereafter, the slides 
already incubated with anti-gremlin or VEGFR2 antibody 
(Supplementary Table S4, part 2), were incubated with 
Alexa Fluor 488 anti-rabbit antibody (Invitrogen) (dilution 
1:1000) for one hour at RT. The rest of the protocol is 
described in Supplementary Methods. 
Western blotting (WB) and immunoprecipitation 
(IP)
The Western blotting analyses of gremlin, YY1, 
c-MYC, HDAC2 and MCL1 were made using 20 μg of 
protein extracts and the antibodies listed in Supplementary 
Table S4, part 3. Anti-actin antibody (1:2500; A2066; 
Sigma-Aldrich, St. Louis, MO) was used to ensure equal 
protein loading and to normalise the results. 
The IP/WB analysis was made in order to evaluate 
the interaction between YY1 and HDAC2: equal amounts 
(300 µg) of protein lysates were precipitated by means 
of incubation with Protein A Sepharose (Amersham 
Biosciences, Piscataway, NJ) and 1 μl of anti-YY1 
antibody. Anti-YY1 and HDAC2 antibodies (the same as 
those used for IHC) were used for the Western blotting. 
Vorinostat treatment of the myxoid liposarcoma 
cell line
Cell line 402-91, a recognised liposarcoma cell 
line [10], was treated with vorinostat (Cat. NoS1047-
SAHA MK0683, Selleck Chemical, Houston, TX). 
The proliferation (MTT) and Trypan blue assays were 
carried out as described in Supplementary Methods. 
Western blotting of c-MYC was carried out using proteins 
extracted from untreated and treated cells under previously 
described conditions. 
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